New antibody shows strong potential against pancreatic cancer

Blocking macropinocytosis changes TME, allows for more effective treatment, preclinical study shows

Blocking macropinocytosis reshapes the tumor microenvironment to be less fibrous and to allow more access to immune cells, according to a preclinical study of pancreatic tumors conducted by scientists at Sanford Burnham Prebys, an NCI-designated Cancer Center.

August 01, 2025

Vol.51 No.30

City of Hope brings evidence-based approaches to integrative oncology

The landscape of cancer care is evolving rapidly, with growing recognition that optimal patient outcomes require a whole-person care approach that goes beyond cytotoxic and targeted therapies.

Six researchers awarded $5.3M for pancreatic cancer research by Stephenson Global

The Stephenson Global Pancreatic Cancer Research Institute and its partner, City of Hope, announced the six inaugural recipients of the Stephenson Scholar Grants, awarding $5.25 million to support high-impact research aimed at transforming the understanding, early detection, and treatment of pancreatic cancer (The Cancer Letter, Sept. 17, 2024).

July 25, 2025

Vol.51 No.29

Clinical Roundup

Study reveals immune-based therapy that may be effective in hard-to-treat lung cancers

A study published today by researchers at the Translational Genomics Research Institute, part of City of Hope, and clinician-scientists at Baylor Scott & White Research Institute revealed a potential new therapeutic strategy for fighting lung cancer that harnesses one of the body’s immune cells, natural killer cells.

July 25, 2025

Vol.51 No.29

Drugs & Targets

EC approves Cabometyx for advanced neuroendocrine tumors

The European Commission has approved Cabometyx (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic and extra-pancreatic neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues.

July 25, 2025

Vol.51 No.29

Imaging’s ride to the bottom in clinical trials—and why it matters now

In cancer care, imaging has become a marvel of modern medicine. Advances in scanner technology, reconstruction algorithms, contrast agents, and diagnostic protocols have radically improved our ability to detect, track, and understand disease. Clinically, imaging is fast, accurate, and central to decision-making.

July 18, 2025

Vol.51 No.28

By Jeff Sorenson